Business Wire

EURID

4.2.2020 12:26:07 CET | Business Wire | Press release

Share
1st AI-driven proactive suspension system for domain names

Over 3.6 million .eu domain names are registered by businesses and private individuals. EURid, the organization that manages the .eu internet space, has launched an award winning AI-driven system that can detect which .eu domain names will be used for malicious purposes, and automatically suspends those before they can do any harm.

Project APEWS – Advanced Prediction and Early Warning System – is the first ever system that can detect domain name abuse before it takes place and bases its decisions on novel machine learning algorithms developed at KU Leuven.

In 75% of the cases where the system flagged a domain name, the prediction was confirmed by third-party abuse indicators. Since its deployment, over 60.000 malicious .eu domain name registrations were correctly identified.

CEO Marc Van Wesemael: “Creating a trustworthy .eu space is our primary goal. APEWS is the flagship of our prevention strategy. It has a deterrent effect on cybercriminals, making .eu domains safer for its users.”

Detecting abuse at the earliest possible

Cybercriminals use domain names to send spam, to distribute malware or to set up a botnet (a network of private computers infected with malicious software and controlled as a group). Until recently, blacklists were the best way to react to these attacks. Subscribers could block incoming or outgoing communication with ‘bad’ domain names on the list. But blacklists can only be used once the harm has already been done.

APEWS, on the other hand, kicks in at the very beginning: when a .eu domain name is registered. EURid worked on APEWS alongside with KU Leuven for four years.

First, parts of the 3.6 million .eu domain names were matched against blacklists. Every detail of the matching domain names was then used to train the predictive model. This resulted in a comprehensive scoring model.

APEWS now continuously watches over the safety of the .eu cyberspace. Every newly registered domain name is scored on these predictive indicators. If the score is too low, the domain name is automatically suspended before it’s active.

This process discourages cybercriminals to use a .eu domain name in the first place. The system continuously learns from previous experience, making it more and more difficult for cybercriminals to avoid detection.

About EURid

EURid is the not-for-profit organisation that operates the .eu, .ею and .ευ top-level domains, following a tender process and appointment by the European Commission. EURid works with over 700 accredited registrars. As part of its ongoing commitment to data security, EURid has been certified for the ISO27001 security standard since 2013. EURid is also registered by the EU Eco-Management and Audit Scheme (EMAS), which is an expression of its environmental commitment. EURid has its headquarters in Diegem (Belgium), and regional offices in Pisa (Italy), Prague (the Czech Republic) and Stockholm (Sweden). More information at: www.eurid.eu .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye